Background: Studies of nasopharyngeal secretions serve as reliable surrogate to evaluate the involvement of viruses in acute otitis media (AOM) and upper/lower respiratory tract infections (URIs/LRIs). We explored nasopharyngeal viral studies from children with uncomplicated AOM and examined their cost-effectiveness in relation to their age., Methods: We identified children aged 0-6 years admitted to our pediatrics department in a university-affiliated, secondary hospital with uncomplicated AOM and concurrent URI/LRI between 2012 and 2017, during October-April, when viral studies are performed. Studies were performed either using antigen detection tests, for respiratory syncytial virus (RSV) and influenza A/B (2012-2016) and for a variety of other common respiratory viruses, utilizing multiplex polymerase chain reaction assays (2017)., Results: A total of 249 children were included (median age: 15 months). In 88 (35%) children, viral studies were positive, most of them in children 24 months (78, 89%). RSV was positive in 52 (59%) children, followed by influenza A and B, in 11 (13%) and 5 (6%) children, respectively. First year switch to a molecular assay, 4.5-fold more expensive, resulted in a statistically significant higher yield: 69% positive results in 24 months, and 66% in those aged 12 months (p < 0.05). In those 24 months, US$23 and US$95 were spent for one positive test in the antigen detection years and the polymerase chain reaction year, respectively, whereas in those >24 months, US$83 and US$878 were invested for one positive test in the same year, respectively., Conclusion: In cost-effectiveness terms, the greatest benefit of nasopharyngeal studies was highest in children 24 months. Copyright © The Author(s), 2019.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Marom, T., Fellner, A., Hirschfeld, Z., Lazarovitch, T., Gavriel, H., Muallem-Kalmovich, L., & Pitaro, J. (2019). The yield of respiratory viruses detection testing is age-dependent in children with acute otitis media. Therapeutic Advances in Infectious Disease, 6, 204993611987112. https://doi.org/10.1177/2049936119871127